Drug-induced osteomalacia;Osteomalacia da farmaci

Recenti Progressi in Medicina

Volumn 89, Issue 10, 1998, Pages 529-533

  D'Erasmo, Emilio ^a   Ragno, Alessandro ^a   Raejntroph, Natalia ^a   Pisani, Daniela ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Drugs; Mineral metabolism; Osteomalacia

Indexed keywords

ALUMINUM; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CADMIUM; COLESTYRAMINE; FLUORIDE; IRON SACCHARATE; ISONIAZID; LEAD; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; VITAMIN D;

BONE MINERALIZATION; CALCIUM BALANCE; CALCIUM HOMEOSTASIS; DRUG INDUCED DISEASE; HUMAN; OSTEOMALACIA; PHOSPHATE BALANCE; REVIEW; VITAMIN D METABOLISM;

HOMEOSTASIS; HUMANS; MINERALS; OSTEOMALACIA; PHARMACEUTICAL PREPARATIONS; PHOSPHORUS; VITAMIN D;

EID: 0032426421     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Mazzuoli GF, D'Erasmo E, Minisola S. La terapia delle malattie metaboliche scheletriche: farmaci attivi sul rimodellamento scheletrico. In: Zoppini A, Farmacologia clinica reumatologica. Milano: Masson Italia 1987; 177-98.
2. Caniggia A. Le osteomalacie. Atti XCII Congresso Soc It Med Int. Roma: L. Pozzi 1991; 235-43.
3. Francis RM, Selby PL. Osteomalacia. Baillière's Clin Endocrinol Metab 1997; 11: 145-63.
4. rd ed Lippincott-Raven 1996; 333-7.
5. Drezner MK. Metabolic Bone Disease. In: Kelley WN ed. Textbook of Internal Medicine. Philadelphia: Lippincott-Raven Publishers 1997; 2257-68.
6. 3 in treatment of osteomalacia associated with ileal resection and cholestyramine theraphy. Gastroenterology 1978; 74: 900-2.
7. Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 1970; 4: 73-6.
8. Offermann G, Pinto V, Kruse R. Antiepileptic drugs and vitamin D supplementation. Epilepsia 1979; 20: 3-15.
9. Hunt PA, Wu-Chen ML, Handal NJ, et a. Bone disease induced by anticonvulsant theraphy and treatment with calcitriol. Am J Dis Child 1986; 140: 715-8.
10. Ashworth B, Horn DB. Evidence of osteomalacia in an outpatient group of adult epileptics. Epilepsia 1977; 18: 37-43.
11. Pylypchuk G, Oreopoulos DG, Wilson DR, et al. Calcium metabolism in adult outpatients with epilepsy receiving long-term anticonvulsant therapy. Can Med Ass J 1978; 118: 635-8.
12. Fogelman I, Gray JM, Gardner MD, et al. Do anticonvulsant drugs commonly induce osteomalacia? Scott Med J 1982; 27: 136-42.
13. 3. Ann Rev Nutr 1988; 8: 75-998.
14. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan NA. A Comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. QJ Med 1986; 59: 569-77.
15. Hahn TJ, Hendin BA, Scharp CR, Haddad JGJ. Effect of chronic anticonvulsant therapy on serum hydroxycalciferol levels in adults. N Engl J Med 1972; 287: 900-4.
16. 3-mediated calcium absorptive mechanism in organ-cultured duodenum. Biochem. Pharmacol 1976; 25: 863-4.
17. Perry W, Erooga MA, Brown J, Stamp TC. Calcium metabolism during rifampicin and isoniazid therapy for tubercolosis. JR Soc Med 1982; 75: 533-6.
18. Chang TY. Osteomalacia during rifampicin and isoniazid therapy is rare in Hong-Kong. Int J Clin Pharmacol Ther 1996; 34: 533-4.
19. Godsall JW, Baron R, Insogna KL. Vitamin D metabolism and bone histomorphometry in a patient with antacid-induced osteomalacia. Am J Med 1984; 77: 747-50.
20. Pivnik E.K, Kerr NC, Kaufman RA, Jones DP, Chesney RW. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr 1995; 34: 73-8.
21. Boutsen Y, Devogelaer JP, Malghem J, Noel H, Nagant De Deuxchaisnes. Antacid-induced osteomalacia. Clin Rheumatol 1996; 15: 75-80.
22. Kassem M, Eriksen EF, Melsen F, Mosekilde L. Antacid-induced osteomalacia: a case report with histomorphometric analysis. J Intern Med 1991; 229: 275-9.
23. Honda R, Tsuritani I, Ishizaki M, Yamada Y. Zinc and copper levels in ribs of cadmium-exposed persons with special reference to osteomalacia. Environ Res 1997; 75: 41.
24. Sato K, Nohtomi K, Demura H, et al. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1-25-dihydroxy-vitamin D production in renal tubules. Bone 1997; 21: 57-64.
25. Siberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.
26. Boyce BF, Smith T, Fogelman I, Johnston E, Ralston S, Boyle IT. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984; 1: 821-4.
27. Adamson BB, Gallagher SJ, Byors J, Ralston SH, Boyle IT, Boyce BF. Mineralization defects with pamidronate therapy Paget's disease. Lancet 1993; 342: 1459-60.
28. Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 1983; 222: 330-332.
29. Jowsey J, Riggs BL, Kelly PJ, Hoffmann D L. Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis. Am J Med 1972; 53: 43-9.
30. Compston JE, Chadha S, Merrett AL. Osteomalacia developing during treatment of osteoporosis with sodium fluoride and vitamin D. Br Med J 1980; 281: 910-1.
31. Kleerekoper M, Mendlovic DB. Sodium fluoride therapy of postmenopausal women. Endocr Rev 1993; 14: 312-23.
32. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-9.
33. Turner CH, Owan I, Brizendine EJ, Zhang W, Wilson ME, Dunipace AJ. High fluoride intakes causes osteomalacia and diminished bone strength in rats with renal deficiency. Bone 1996; 19: 595-601.
34. Gutteridge DH, Price RI, Kent GN, Prince RL, Michell PA. Spontaneous hip fractures in fluoride-treated patients: potential causative factors. J Bone Min Res Suppl 1, S205-S215, 1990.
35. Goodman WG, Leite-Duarte ME. Aluminium: effects on bone and role in the pathogenesis of renal osteodystrophy. Min Electrolyte Metab 1991; 17: 221-32.
36. Nebeker HG, Coburn JW. Aluminium and renal osteodystrophy. Ann Rev Med 1986; 37: 79-95.
37. Klein GL, Alfrey AC, Miller NL, et al. Aluminium loading during total parenteral nutrition. Am J Clin Nutr 1982; 35: 1425-9.
38. Vargas JH, Klein GL, Ament ME, et al. Metabolic bone disease of total parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminium content. Am J Clin Nutr 1988; 48: 1070-8.
39. Malluche HA, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 1984; 311: 140-4.
40. Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llach F. Desferrioxamine therapy in hemodialysis patients with aluminium-associated bone disease. Kidney Int 1989; 35: 1371-8.